About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Stroke is a medical emergency and one of the leading causes of death and disability worldwide. In this context, the Neurovascular Diseases Group was established in 2001, focusing on biomedical research into both ischemic and hemorrhagic stroke from a basic and translational perspective. Our work in this research field has covered the entire disease spectrum, from prevention and treatment to recovery. In 2017, we expanded our research interests to include vascular dementia and Alzheimer’s disease, related to the β-amyloid protein. Our ultimate goal as a research team is to help answer critical questions that will improve the clinical management of stroke and dementia, conditions with significant health impacts due to their high prevalence and associated disability. We are also committed to promoting scientific education among researchers and the society, and to fostering public engagement in these areas.
Since 2001, dozens of researchers have carried out their work in this laboratory, and as a team we have leaded translational and clinical projects through both preclinical studies with experimental models, as well as cohort studies in patients. The laboratory stands out for its extensive national and international collaborations, working closely with other research groups and the biomedical industry.
Our research focuses on identifying new therapeutic targets for cerebroprotection and brain repair, discovering diagnostic, prognostic, and recovery biomarkers in both biological fluids and neuroimaging, and investigating the mechanisms of neuronal and vascular damage. We also work in regenerative medicine and nanomedicine fields, with strong expertise in preclinical models of stroke, cerebral amyloidosis, and Alzheimer’s disease. More specifically, our main research lines are:
IP: - Collaborators: Maria Pilar Delgado Martínez Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 27950.35 Reference: SLT021/21/000027 Duration: 01/04/2022 - 31/12/2024
IP: Anna Rosell Novel Collaborators: Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Jesús Pizarro Gonzálvez Funding agency: Instituto de Salud Carlos III Funding: 250214.8 Reference: RD21/0006/0007 Duration: 01/01/2022 - 31/12/2024
IP: Joan Montaner Villalonga Collaborators: Anna Penalba Morenilla, PRESTIGE-AF: PREvention of STroke in Intracerebral hemorrhaGE survivors with Atrial Fibrillation, Ariadna Martín Balcells, Olalla Pancorbo Rosal, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi Funding agency: EUROPEAN COMMISSION Funding: 481723 Reference: PRESTIGE-AF_H2020SC12017 Duration: 01/12/2017 - 30/11/2024
IP: Joan Montaner Villalonga Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 91282.5 Reference: AFFECT-EU_H2020_SC1BHC2019 Duration: 01/01/2020 - 31/03/2024
The Neurovascular Diseases group at VHIR will use disease models to study its pathophysiological mechanisms.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.
